Bfsg LLC Sells 767 Shares of Johnson & Johnson (NYSE:JNJ)

Bfsg LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,490 shares of the company’s stock after selling 767 shares during the period. Bfsg LLC’s holdings in Johnson & Johnson were worth $3,686,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Buckingham Capital Management Inc. raised its stake in Johnson & Johnson by 2.5% in the fourth quarter. Buckingham Capital Management Inc. now owns 12,374 shares of the company’s stock worth $1,789,000 after buying an additional 303 shares in the last quarter. BKM Wealth Management LLC raised its stake in Johnson & Johnson by 1.5% in the fourth quarter. BKM Wealth Management LLC now owns 14,524 shares of the company’s stock worth $2,100,000 after buying an additional 212 shares in the last quarter. Kestra Investment Management LLC grew its holdings in Johnson & Johnson by 16.7% in the fourth quarter. Kestra Investment Management LLC now owns 24,422 shares of the company’s stock worth $3,532,000 after purchasing an additional 3,499 shares during the period. Atria Wealth Solutions Inc. grew its holdings in Johnson & Johnson by 1.7% in the fourth quarter. Atria Wealth Solutions Inc. now owns 162,782 shares of the company’s stock worth $23,542,000 after purchasing an additional 2,784 shares during the period. Finally, Kornitzer Capital Management Inc. KS grew its holdings in Johnson & Johnson by 1.5% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 349,105 shares of the company’s stock worth $50,488,000 after purchasing an additional 5,251 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on JNJ shares. Barclays upped their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Finally, Morgan Stanley cut their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.7 %

Shares of Johnson & Johnson stock opened at $162.35 on Friday. The company has a market cap of $390.87 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. The company’s 50 day moving average is $148.93 and its 200 day moving average is $155.90. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the firm earned $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.06%. Johnson & Johnson’s payout ratio is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.